Carolyn Russo1,2, Linda Stout2,3, Toni House2, Victor M Santana3,4. 1. Department of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee. 2. Affiliate Program, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, Tennessee.
Abstract
INTRODUCTION: Major advances in the field of pediatric oncology have resulted from rigorous, prospective clinical oncology research trials. Optimizing access for all children and adolescents to clinical research trials is an important goal. Barriers to clinical trial enrollment are numerous, involving the health care system, research infrastructure, access to care, providers, and participants. The perspectives of pediatric oncologists may provide insight into the barriers of clinical trial enrollment for this unique population. METHODS AND MATERIALS: We conducted qualitative structured interviews over two months of pediatric oncologists in a community-based clinical network as part of a quality improvement project aimed at increasing enrollment rates at St. Jude Affiliate Clinics. We assessed barriers and facilitators to clinical trial opportunities for racial and ethnic minority pediatric participants. In the same fiscal year of the interviews, we tracked clinical trial enrollment by race and ethnicity of the participant over 12 months. RESULTS: The major barriers to clinical trial enrollment for pediatric cancer minority participants included language discordance, travel difficulties, and complex trial designs. In contrast, the major facilitators included building trust with participants and their parents, and education on the merits of clinical research studies. We did not observe any disparities in clinical trial enrollment among the racial and ethnic minority participants of the clinical trials conducted across our network of pediatric oncology clinics. CONCLUSIONS: Identifying barriers and facilitators may improve clinical trial enrollment for underrepresented participant groups.
INTRODUCTION: Major advances in the field of pediatric oncology have resulted from rigorous, prospective clinical oncology research trials. Optimizing access for all children and adolescents to clinical research trials is an important goal. Barriers to clinical trial enrollment are numerous, involving the health care system, research infrastructure, access to care, providers, and participants. The perspectives of pediatric oncologists may provide insight into the barriers of clinical trial enrollment for this unique population. METHODS AND MATERIALS: We conducted qualitative structured interviews over two months of pediatric oncologists in a community-based clinical network as part of a quality improvement project aimed at increasing enrollment rates at St. Jude Affiliate Clinics. We assessed barriers and facilitators to clinical trial opportunities for racial and ethnic minority pediatric participants. In the same fiscal year of the interviews, we tracked clinical trial enrollment by race and ethnicity of the participant over 12 months. RESULTS: The major barriers to clinical trial enrollment for pediatric cancer minority participants included language discordance, travel difficulties, and complex trial designs. In contrast, the major facilitators included building trust with participants and their parents, and education on the merits of clinical research studies. We did not observe any disparities in clinical trial enrollment among the racial and ethnic minority participants of the clinical trials conducted across our network of pediatric oncology clinics. CONCLUSIONS: Identifying barriers and facilitators may improve clinical trial enrollment for underrepresented participant groups.
Authors: Sandra E Brooks; Carolyn Y Muller; William Robinson; Eleanor M Walker; Kate Yeager; Elise D Cook; Sue Friedman; Carol P Somkin; Carol Leslie Brown; Worta McCaskill-Stevens Journal: J Oncol Pract Date: 2015-10-13 Impact factor: 3.840
Authors: Lauren M Hamel; Louis A Penner; Terrance L Albrecht; Elisabeth Heath; Clement K Gwede; Susan Eggly Journal: Cancer Control Date: 2016-10 Impact factor: 3.302
Authors: P N Lara; R Higdon; N Lim; K Kwan; M Tanaka; D H Lau; T Wun; J Welborn; F J Meyers; S Christensen; R O'Donnell; C Richman; S A Scudder; J Tuscano; D R Gandara; K S Lam Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Robert S Mannel; Joan L Walker; Natalie Gould; Dennis R Scribner; Scott Kamelle; Todd Tillmanns; D Scott McMeekin; Michael A Gold Journal: Am J Clin Oncol Date: 2003-04 Impact factor: 2.339
Authors: Neal J Meropol; Joanne S Buzaglo; Jennifer Millard; Nevena Damjanov; Suzanne M Miller; Caroline Ridgway; Eric A Ross; John D Sprandio; Perry Watts Journal: J Natl Compr Canc Netw Date: 2007-09 Impact factor: 11.908
Authors: Jingyi Zhang; Harriette G C Van Spall; Yaoyao Wang; Lehana Thabane; Ruoting Wang; Guowei Li Journal: BMC Med Date: 2022-09-16 Impact factor: 11.150
Authors: Dylan E Graetz; Arshia Madni; Jeffrey Gossett; Guolian Kang; Janice A Sabin; Victor M Santana; Carolyn L Russo Journal: Cancer Date: 2020-10-29 Impact factor: 6.860